Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating deseases, such as cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating deseases, such as cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

A method for preparing (dimethylaminomethylene) malononitrile by using a micro reaction system. Cyanoacetamide, N,N-dimethylformamide and a catalyst are mixed to obtain a mixture, and the mixture and phosphorus oxychloride are simultaneously pumped into the micro reaction system that includes a micromixer and a microchannel reactor connected in series for continuous dehydration condensation. After adjusted to a target pH, the crude product is subjected to continuous liquid-liquid extraction with an organic solvent in a centrifugal extraction unit comprising a plurality of annular centrifugal extractors connected in series. The organic phase is collected to obtain the target product (dimethyl aminomethylene) malononitrile.

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating deseases, such as cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

The present invention relates to a compound of formula (I): ##STR00001## in which: the R.sub.1 and R.sub.2 groups, which may be identical or different, are, independently of one another, a saturated or unsaturated, linear, branched or cyclic hydrocarbon group having from 1 to 15 carbon atoms, preferably from 1 to 10 carbon atoms; the R.sub.3 and R.sub.4 groups, which may be identical or different, are selected, independently of one another, from a hydrogen atom, a methyl group or an ethyl group; the R, R.sub.6 and R.sub.7 groups, which may be identical or different, are selected, independently of one another, from a hydrogen atom or an alkyl group comprising from 1 to 6 carbon atoms; n is an integer of 0 to 20; and m is an integer of 1 to 6.

The present invention relates to a compound of formula (I): ##STR00001## in which: the R.sub.1 and R.sub.2 groups, which may be identical or different, are, independently of one another, a saturated or unsaturated, linear, branched or cyclic hydrocarbon group having from 1 to 15 carbon atoms, preferably from 1 to 10 carbon atoms; the R.sub.3 and R.sub.4 groups, which may be identical or different, are selected, independently of one another, from a hydrogen atom, a methyl group or an ethyl group; the R, R.sub.6 and R.sub.7 groups, which may be identical or different, are selected, independently of one another, from a hydrogen atom or an alkyl group comprising from 1 to 6 carbon atoms; n is an integer of 0 to 20; and m is an integer of 1 to 6.

Process for preparation of a mixture of methyl glycine diacetic acid (MGDA) or its respective mono-, di-, trialkali metal salt or its respective mono-, di- or tri-ammonium salt or mixtures thereof, and glutamic acid diacetic acid (GLDA) or its respective mono-, di-, tri-, or tetra-alkali metal or mono-, di-, tri- or tetra-ammonium salt or mixtures thereof, wherein said process com-prises the steps of: (a) dissolution in water of (a1) alanine in its L- or D-enantiomeric form or its respective monoalkali metal salt or mixtures thereof, and (a2) glutamic acid as L- or D-enantiomer or its respective mono-, or dialkali metal or mixtures thereof, wherein the molar ratio of alanine to glutamic acid is in the range of from 1:9 to 9:1, (b) converting the mixture obtained in step (a) with formaldehyde and hydrocyanic acid or alkali metal cyanide to the corresponding dinitriles, (c) saponification of the dinitriles resulting from step (b).

Process for preparation of a mixture of methyl glycine diacetic acid (MGDA) or its respective mono-, di-, trialkali metal salt or its respective mono-, di- or tri-ammonium salt or mixtures thereof, and glutamic acid diacetic acid (GLDA) or its respective mono-, di-, tri-, or tetra-alkali metal or mono-, di-, tri- or tetra-ammonium salt or mixtures thereof, wherein said process com-prises the steps of: (a) dissolution in water of (a1) alanine in its L- or D-enantiomeric form or its respective monoalkali metal salt or mixtures thereof, and (a2) glutamic acid as L- or D-enantiomer or its respective mono-, or dialkali metal or mixtures thereof, wherein the molar ratio of alanine to glutamic acid is in the range of from 1:9 to 9:1, (b) converting the mixture obtained in step (a) with formaldehyde and hydrocyanic acid or alkali metal cyanide to the corresponding dinitriles, (c) saponification of the dinitriles resulting from step (b).

The present invention relates to a non-aqueous electrolyte additive, and a non-aqueous electrolyte for a lithium secondary battery including the same and a lithium secondary battery, and particularly, to a non-aqueous electrolyte additive having a nitrile group and a propargyl group, and a non-aqueous electrolyte for a lithium secondary battery and a lithium secondary battery, which include the non-aqueous electrolyte additive so that capacity and cycle lifespan characteristics at high temperature can be improved.

The present invention relates to a non-aqueous electrolyte additive, and a non-aqueous electrolyte for a lithium secondary battery including the same and a lithium secondary battery, and particularly, to a non-aqueous electrolyte additive having a nitrile group and a propargyl group, and a non-aqueous electrolyte for a lithium secondary battery and a lithium secondary battery, which include the non-aqueous electrolyte additive so that capacity and cycle lifespan characteristics at high temperature can be improved.